Clinical Trial Update: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial of AZD4512 as monotherapy or with anticancer agents in relapsed/refractory B-cell non-Hodgkin lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• AZD4512

Snippet

Sponsor: AstraZeneca | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING